Improving intestinal absorption and oral bioavailability of curcumin via taurocholic acid-modified nanostructured lipid carriers

International Journal of Nanomedicine

Volumn 12, Issue , 2017, Pages 7897-7911

  Tian, Cihui ^a   Asghar, Sajid ^b   Wu, Yifan ^a   Chen, Zhipeng ^c   Jin, Xin ^a   Yin, Lining ^a   Huang, Lin ^a   Ping, Qineng ^a   Xiao, Yanyu ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b GOVERNMENT COLLEGE UNIVERSITY   (Pakistan)

^c NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

Bioavailability; Curcumin; Nanostructured lipid carriers; Oral administration; Pharmacokinetics; Taurocholic acid

Indexed keywords

CURCUMIN; MACROGOL STEARATE; NANOMATERIAL; NANOSTRUCTURED LIPID CARRIER; TAUROCHOLIC ACID; UNCLASSIFIED DRUG; DRUG CARRIER; LIPID; MACROGOL DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG FORMULATION; DRUG TRANSFORMATION; IN VITRO STUDY; IN VIVO STUDY; INTESTINE ABSORPTION; INTESTINE MUCOSA PERMEABILITY; INTESTINE PERFUSION; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; RAT; SUSTAINED DRUG RELEASE; ZETA POTENTIAL; ANIMAL; BIOAVAILABILITY; CHEMISTRY; DRUG EFFECTS; ORAL DRUG ADMINISTRATION; PERMEABILITY; SPRAGUE DAWLEY RAT;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; CURCUMIN; DRUG CARRIERS; INTESTINAL ABSORPTION; LIPIDS; MALE; NANOSTRUCTURES; PARTICLE SIZE; PERMEABILITY; POLYETHYLENE GLYCOLS; RATS, SPRAGUE-DAWLEY; TAUROCHOLIC ACID;

EID: 85032711036     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S145988     Document Type: Article

References (52)

1. Fletcher J, Wirz A, Young J, Vallance R, McColl KE. Unbuffered highly acidic gastric juice exists at the gastroesophageal junction after a meal. Gastroenterology. 2001;121(4):775–783.
2. Mao HQ, Roy K, Troung-Le VL, et al. Chitosan-DNA nanoparticles as gene carriers: synthesis, characterization and transfection efficiency. J Control Release. 2001;70(3):399–421.
3. 12 pathway to enhance oral drug delivery via polymeric micelles. Biomacromolecules. 2005;6(5):2462–2467.
4. Roger E, Kalscheuer S, Kirtane A, et al. Folic acid functionalized nanoparticles for enhanced oral drug delivery. Mol Pharm. 2012;9(7): 2103–2110.
5. Mirvish SS. Bile acids and other lipids in the gall-bladder biles of Africans with primary cancer of the liver. Br J Cancer. 1964;18(3):478–483.
6. Park K, Lee GY, Kim YS, et al. Heparin-deoxycholic acid chemical conjugate as an anticancer drug carrier and its antitumor activity. J Control Release. 2006;114(3):300–306.
7. Park KS, Lee SK, Son DH, et al. The attenuation of experimental lung metastasis by a bile acid acylated-heparin derivative. Biomaterials. 2007;28(16):2667–2676.
8. Khatun Z, Nurunnabi M, Cho KJ, Byun Y, Bae YH, Lee YK. Oral absorption mechanism and anti-angiogenesis effect of taurocholic acid-linked heparin-docetaxel conjugates. J Control Release. 2014;177:64–73.
9. Naksuriya O, Okonogi S, Schiffelers RM, Hennink WE. Curcumin nanoformulations: a review of pharmaceutical properties and preclinical studies and clinical data related to cancer treatment. Biomaterials. 2014; 35(10):3365–3383.
10. Nayak AP, Tiyaboonchai W, Patankar S, Madhusudhan B, Souto EB. Curcuminoids-loaded lipid nanoparticles: novel approach towards malaria treatment. Colloids Surf B Biointerfaces. 2010;81(1):263–273.
11. Shim JS, Kim JH, Cho HY, et al. Irreversible inhibition of CD13/ aminopeptidase N by the antiangiogenic agent curcumin. Chem Biol. 2003;10(8):695–704.
12. Lin JK, Lin-Shiau SY. Mechanisms of cancer chemoprevention by curcumin. Proc Natl Sci Counc Repub China B. 2001;25(2):59–66.
13. Dhillon N, Aggarwal BB, Newman RA, et al. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res. 2008; 14(14):4491–4499.
14. Vareed SK, Kakarala M, Ruffin MT, et al. Pharmacokinetics of curcumin conjugate metabolites in healthy human subjects. Cancer Epidem Biomarkers Prev. 2008;17(6):1411–1417.
15. Wahlström B, Blennow G. A study on the fate of curcumin in the rat. Acta Pharmacol Toxicol (Copenh). 1978;43(2):86–92.
16. Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery: a review of the state of the art. Eur J Pharm Biopharm. 2000;50(1):161–177.
17. Müller RH, Mehnert W, Lucks JS, et al. Solid lipid nanoparticles (SLN): an alternative colloidal carrier system for controlled drug delivery. Eur J Pharm Biopharm. 1995;41(1):62–69.
18. Attama AA, Schicke BC, Paepenmüller T, Müller-Goymann CC. Solid lipid nanodispersions containing mixed lipid core and a polar hetero-lipid: characterization. Eur J Pharm Biopharm. 2007;67(1):48–57.
19. Meng F, Asghar S, Gao S, et al. A novel LDL-mimic nanocarrier for the targeted delivery of curcumin into the brain to treat Alzheimer’s disease. Colloids Surf B Biointerfaces. 2015;134:88–97.
20. Ding F, Huang J, Lin J, et al. A study of the binding of CI mordant red 3 with bovine serum albumin using fluorescence spectroscopy. Dyes Pigm. 2009;82(1):65–70.
21. Meng FF, Asghar S, Xu YR, et al. Design and evaluation of lipoprotein resembling curcumin-encapsulated protein-free nanostructured lipid carrier for brain targeting. Int J Pharm. 2016;506(1–2):46–56.
22. Yang L, Gao S, Asghar S, et al. Hyaluronic acid/chitosan nanoparticles for delivery of curcuminoid and its in vitro evaluation in glioma cells. Int J Biol Macromol. 2015;72:1391–1401.
23. Mohanty C, Sahoo SK. The in vitro stability and in vivo pharmacokinetics of curcumin prepared as an aqueous nanoparticulate formulation. Biomaterials. 2010;31(25):6597–6611.
24. Puvvada N, Rajput S, Kumar BN, Mandal M, Pathak A. Exploring the fluorescence switching phenomenon of curcumin encapsulated niosomes: in vitro real time monitoring of curcumin release to cancer cells. RCS Adv. 2013;3(8):2553–2557.
25. Peracchia MT, Vauthier C, Passirani C, Couvreur P, Labarre D. Complement consumption by poly(ethylene glycol) in different conformations chemically coupled to poly(isobutyl 2-cyanoacrylate) nanoparticles. Life Sci. 1997;61(7):749–761.
26. Su Z, Niu J, Xiao Y, et al. Effect of octreotide-polyethylene glycol(100) monostearate modification on the pharmacokinetics and cellular uptake of nanostructured lipid carrier loaded with hydroxycamptothecine. Mol Pharm. 2011;8(5):1641–1651.
27. Zhang Y, Huo MR, Zhou JP, et al. DDSolver: an add-in program for modeling and comparison of drug dissolution profiles. AAPS J. 2010; 12(3):263–271.
28. Rathore R, Jain JP, Srivastava A, Jachak SM, Kumar N. Simultaneous determination of hydrazinocurcumin and phenol red in samples from rat intestinal permeability studies: HPLC method development and validation. J Pharm Biomed Anal. 2008;46(2):374–380.
29. Dezani TM, Dezani AB, Junior JB, Serra CH. Single-pass intestinal perfusion (SPIP) and prediction of fraction absorbed and permeability in humans: a study with antiretroviral drugs. Eur J Pharm Biopharm. 2016;104:131–139.
30. Jain R, Duvvuri S, Kansara V, Mandava NK, Mitra AK. Intestinal absorption of novel-dipeptide prodrugs of saquinavir in rats. Int J Pharm. 2007;336(2):233–240.
31. Lim SJ, Kim CK. Formulation parameters determining the physico-chemical characteristics of solid lipid nanoparticles loaded with all-trans retinoic acid. Int J Pharm. 2002;243(1):135–146.
32. Luo Y, Zhang Y, Pan K, Critzer F, Davidson PM, Zhong Q. Self-emulsification of alkaline-dissolved clove bud oil by whey protein, gum arabic, lecithin, and their combinations. J Agric Food Chem. 2014; 62(19):4417–4424.
33. Su Z, Shi Y, Xiao Y, et al. Effect of octreotide surface density on receptor-mediated endocytosis in vitro and anticancer efficacy of modified nanocarrier in vivo after optimization. Int J Pharm. 2013;447(1):281–292.
34. Luo Y, Teng Z, Li Y, Wang Q. Solid lipid nanoparticles for oral drug delivery: chitosan coating improves stability, controlled delivery, mucoad-hesion and cellular uptake. Carbohydr Polym. 2015;122:221–229.
35. Sanphui P, Goud NR, Khandavilli UB, Bhanoth S, Nangia A. New polymorphs of curcumin. Chem Commun. 2011;47(17):5013–5015.
36. Fang JY, Fang CL, Liu CH, Su YH. Lipid nanoparticles as vehicles for topical psoralen delivery: solid lipid nanoparticles (SLN) versus nanostructured lipid carriers (NLC). Eur J Pharm Biopharm. 2008;70(2): 633–640.
37. Sahu A, Kasoju N, Bora U. Fluorescence study of the curcumin-casein micelle complexation and its application as a drug nanocarrier to cancer cells. Biomacromolecules. 2008;9(10):2905–2912.
38. Leung MH, Kee TW. Effective stabilization of curcumin by association to plasma proteins: human serum albumin and fibrinogen. Langmuir. 2009;25(10):5773–5777.
39. Rieux AD, Pourcelle V, Cani PD, Marchand-Brynaert J, Préat V. Targeted nanoparticles with novel non-peptidic ligands for oral delivery. Adv Drug Deliv Rev. 2013;65(6):833–844.
40. Soong R, Macdonald PM. PEG molecular weight and lateral diffusion of PEG-ylated lipids in magnetically aligned bicelles. Biochim Biophys Acta. 2007;1768(7):1805–1814.
41. Gref R, Domb A, Quellec P, et al. The controlled intravenous delivery of drugs using PEG-coated sterically stabilized nanospheres. Adv Drug Delivery Rev. 1995;16(2):215–233.
42. Papadopoulou V, Kosmidis K, Vlachou M, Macheras P. On the use of the Weibull function for the discernment of drug release mechanisms. Int J Pharm. 2006;309(1):44–50.
43. Dahan A, West BT, Amidon GL. Segmental-dependent membrane permeability along the intestine following oral drug administration: evaluation of a triple single-pass intestinal perfusion (TSPIP) approach in the rat. Eur J Pharm Sci. 2009;36(2):320–329.
44. Chu XY, Sánchez-Castaño GP, Higaki K, Oh DM, Hsu CP, Amidon GL. Correlation between epithelial cell permeability of cephalexin and expression of intestinal oligopeptide transporter. J Pharmacol Exp Ther. 2001;299(2):575–582.
45. Holmstock NF, Annaert PP, Augustijns P. Boosting of HIV protease inhibitors by ritonavir in the intestine: the relative role of Cyp and P-gp inhibition based on Caco-2 monolayers versus in situ intestinal perfusion in mice. Drug Metab Dispos. 2012;40(8):1473–1477.
46. Zhao B, Fan YC, Wang XQ, Dai WB, Zhang Q, Wang XL. [Cel-lular toxicity and anti-tumor efficacy of iRGD modified doxorubicin loaded sterically stabilized liposomes]. Yao Xue Xue Bao. 2013;48(3): 417–422. Chinese.
47. Dietschy JM. Mechanisms for the intestinal absorption of bile acids. J Lipid Res. 1968;9(3):297–309.
48. Dawson PA, Lan T, Rao A. Bile acid transporters. J Lipid Res. 2009; 50(12):2340–2357.
49. Beloqui A, Solinís MÁ, Rodríguez-Gascón A, Almeida AJ, Préat V. Nanostructured lipid carriers: promising drug delivery systems for future clinics. Nanomedicine. 2016;12(1):143–161.
50. Xiao Y, Chen X, Yang L, et al. Preparation and oral bioavailability study of curcuminoid-loaded microemulsion. J Agric Food Chem. 2013;61(15):3654–3660.
51. Ravindranath V, Chandrasekhara N. Absorption and tissue distribution of curcumin in rats. Toxicology. 1980;16(3):259–265.
52. Shen J, Wang Y, Ping Q, Xiao Y, Huang X. Mucoadhesive effect of thiolated PEG stearate and its modified NLC for ocular drug delivery. J Control Release. 2009;137(3):217–223.